Chronic Use of Valacyclovir
For chronic suppressive therapy of recurrent genital herpes in immunocompetent adults, valacyclovir 500-1000 mg once daily is highly effective and safe for long-term use, with documented safety data extending beyond 1 year and up to 10 years for acyclovir (its parent compound).
Primary Indications for Chronic Valacyclovir
Genital Herpes Suppression
Daily suppressive therapy reduces genital herpes recurrence frequency by ≥75% in patients with frequent recurrences (≥6 episodes per year) 1. The recommended dosing options are:
- Valacyclovir 1000 mg once daily (standard dose)
- Valacyclovir 500 mg once daily (alternative for patients with ≤9 recurrences/year)
- Avoid valacyclovir 500 mg once daily in patients with ≥10 recurrences/year as this dose is less effective 1
For HIV-infected patients with CD4+ counts ≥100 cells/mm³, use valacyclovir 500 mg twice daily 2, 3.
Other Approved Chronic Uses
- Transmission reduction: Valacyclovir 500 mg once daily in source partners with ≤9 recurrences/year reduces transmission risk to susceptible partners 3
- Herpes zoster ophthalmicus: Recent evidence supports 12 months of valacyclovir 1000 mg daily to reduce pain medication requirements and pain duration, particularly in younger patients with chronic disease 4, 5
Duration of Therapy and Reassessment
After 1 year of continuous suppressive therapy, discontinue treatment temporarily to reassess the patient's recurrence rate and psychological adjustment, as recurrence frequency naturally decreases over time in many patients 1. However, this recommendation stems from 1998 guidelines when valacyclovir experience was limited to 1 year 1.
Current evidence supports much longer duration: Safety and efficacy have been documented for acyclovir up to 6 years and valacyclovir for multiple years 1, 6. Studies involving over 3000 patients receiving valacyclovir ≤1000 mg/day for up to 1 year showed safety profiles indistinguishable from placebo 6.
Safety Profile and Monitoring
Adverse Effects
- Most common: Headache and nausea (infrequent) 2
- No routine laboratory monitoring required in patients with normal renal function 2
- Allergic reactions are rare 1
Critical Safety Considerations
Monitor renal function in patients with impaired kidney function. Dose adjustments are required when creatinine clearance <50 mL/min 3:
- CrCl 30-49: No reduction for suppressive therapy
- CrCl 10-29: 500 mg every 24 hours
- CrCl <10: 500 mg every 24 hours
AVOID high-dose valacyclovir (8 g/day) in advanced HIV disease due to risk of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) 2, 1. This complication has NOT been reported at standard suppressive doses (≤1000 mg/day) 2.
Resistance Concerns
Clinically significant acyclovir resistance remains extremely rare (<0.5%) in immunocompetent patients, even with prolonged suppressive therapy 1, 6. Among immunocompromised patients, resistance rates remain low at approximately 5% 6.
If lesions fail to resolve within 7-10 days of treatment, suspect resistance and obtain viral culture with susceptibility testing 2.
Pregnancy Considerations
Valacyclovir safety in pregnancy is not definitively established, though registry data from over 1000 pregnancies show no increased risk of major birth defects compared to the general population 1. Women receiving valacyclovir during pregnancy should be reported to the manufacturer's registry 1.
Key Clinical Pitfalls
Underdosing patients with very frequent recurrences: Use 1000 mg daily or 500 mg twice daily, NOT 500 mg once daily in patients with ≥10 episodes/year 1
Failing to adjust for renal impairment: Always check renal function before initiating chronic therapy and adjust dosing accordingly 3
Using high-dose regimens (>1000 mg/day) in advanced HIV disease: Stick to 500 mg twice daily maximum in HIV-infected patients to avoid TTP/HUS risk 2, 1
Not counseling patients about asymptomatic shedding: Suppressive therapy reduces but does NOT eliminate viral shedding or transmission risk 1
Continuing indefinitely without reassessment: Evaluate need for continuation after 1 year, as natural history may improve over time 1